• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by ImmuCell Corporation (Amendment)

    4/16/21 3:21:48 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $ICCC alert in real time by email
    SC 13D/A 1 brhc10023246_sc13da.htm SC 13D/A
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934
    (Amendment No. 3 )*

    ImmuCell Corporation

    (Name of Issuer)

    Common Stock, $.10 par value

    (Title of Class of Securities)

    452525306

    Cusip Number

    Norman H. Pessin
    Sandra F. Pessin
    Brian L. Pessin
    400 E 51st PH31
    New York, NY 10022
    212-808-4333

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    April 15, 2021

    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement of Schedule 13G to report the acquisition which is the subject of the Schedule 13D, and is filing this schedule because of ss. 240.13d-1(e), ss. 240.13d-1(f) or ss. 240.13d-1(g), check the following box ☐.

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See ss.240.13d-7(b) for other parties to whom copies are to be sent.

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    PAGE 2
    CUSIP No. 452525306
    Schedule 13D

    1
    NAMES OF REPORTING PERSONS
     
     
    Norman H. Pessin
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☑

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    PF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    703,636
     
     
     
     
    8
    SHARED VOTING POWER
     
     

     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    703,636
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     

     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    703,636
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    1) 9.10%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     


    PAGE 3
    CUSIP No. 452525306
    Schedule 13D

    1
    NAMES OF REPORTING PERSONS
     
     
    Sandra F. Pessin
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☑

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    PF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    401,819
     
     
     
     
    8
    SHARED VOTING POWER
     
     

     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    401,819
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     

     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    401,819
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    1) 5.19%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     


    PAGE 4
    CUSIP No. 452525306
    Schedule 13D

    1
    NAMES OF REPORTING PERSONS
     
     
    Brian L. Pessin
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☑

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    PF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    110,682
     
     
     
     
    8
    SHARED VOTING POWER
     
     

     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    110,682
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     

     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    110,682
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    1.43%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     


    PAGE 5
    CUSIP No. 452525306
    Schedule 13D

    Item 1.
    Security and Issuer

    This Schedule 13D relates to the common stock, $.10 par value (the “Common Stock” or the “Shares”),of Immucell Corporation (the “Issuer”), whose principal executive offices are located at 56 Evergreen Drive, Portland, ME 04103.

    Item 2.
    Identity and Background

    This Schedule 13D is being filed by and for Norman H. Pessin, Sandra F. Pessin, and Brian L. Pessin (each a “Reporting Person”). Certain information with respect to each Reporting Person is set forth below:

     
    Name and Address:
    1)
    Norman H. Pessin
    400 East 51st PH31
         
    New York, NY 10022
       
    2)
    Sandra F. Pessin
    400 East 51st PH31
         
    New York, NY 10022
       
    3)
    Brian L. Pessin
    310 East 75th Street, Apt. 2A
         
    New York, NY 10021
           
     
    Principal Occupation:
    1)
    Investor
       
    2)
    Housewife
       
    3)
    Investor
           
     
    Criminal Convictions:
    1)
    None
       
    2)
    None
       
    3)
    None
           
     
    Civil Proceedings:
    1)
    None
       
    2)
    None
       
    3)
    None
           
     
    Citizenship:
    1)
    United States
       
    2)
    United States
       
    3)
    United States

    Item 3.
    Source and Amount of Funds or Other Consideration

    The aggregate purchase price of the 703,636 shares of Common Stock owned by Norman H. Pessin is approximately $3,749,998, including brokerage commissions. The shares of Common Stock owned by Norman H. Pessin were acquired with personal funds. The aggregate purchase price of the 401,819 shares of Common Stock owned by Sandra F. Pessin is approximately $2,667,507, including brokerage commissions. The shares of Common Stock owned by Sandra F. Pessin were acquired with personal funds. The aggregate purchase price of the 110,682 shares of Common Stock owned by Brian L. Pessin is approximately $591,419.86, including brokerage commissions. The shares of Common Stock owned by Brian L. Pessin were acquired with personal funds.


    PAGE 6
    CUSIP No. 452525306
    Schedule 13D

    Item 4.
    Purpose of Transaction

    The Reporting Persons originally purchased the Shares based on the belief that the Shares, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable.

    The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer’s financial position and investment strategy, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, communications with management and the Board of Directors of the Issuer, engaging in discussions with third parties about the Issuer, making proposals to the Issuer concerning changes to the capitalization or operations of the Issuer, purchasing additional Shares, selling some or all of their Shares, engaging in short selling of or any hedging or similar transaction with respect to the Shares, or changing their intention with respect to any and all matters referred to in Item 4.

    Item 5.
    Interest in Securities of the Issuer

    Norman H. Pessin owns 703,636 shares of Common Stock of the Issuer, constituting 9.10% of the outstanding shares thereof. Sandra F. Pessin owns 401,819 shares of Common Stock of the Issuer, constituting 5.19% of the outstanding shares thereof. Brian L. Pessin owns 110,682 shares of Common Stock of the Issuer, constituting 1.43% of the outstanding shares thereof.

    Norman H. Pessin has sole voting and dispositive power with respect to the shares of Common Stock he owns directly. Sandra F. Pessin has sole voting and dispositive power with respect to the shares of Common Stock she owns directly. Brian L. Pessin has sole voting and dispositive power with respect to the shares of Common Stock he owns directly.

    Schedule A attached hereto lists all transactions in securities of the Issuer during the past sixty days by the Reporting Persons. All of such transactions were effected by Securities Purchase Agreement dated April 14, 2021.

    No person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the shares of Common Stock.


    PAGE 7
    CUSIP No. 452525306
    Schedule 13D

    Item 6.
    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

    None.

    Item 7.
    Material to Be Filed as Exhibits

    None.

    Signatures

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    /s/ Norman H. Pessin
    Norman H. Pessin

    /s/ Sandra F. Pessin
    Sandra F. Pessin
     
    /s/ Brian L. Pessin
     Brian L. Pessin
     

    Schedule A

    Transactions in the Securities of the Issuer During the Past 60 Days

    Shares of Common
    Stock Bought
    Price Per
    Share ($)
    Date of
    Purchase
         
     
    Sandra F. Pessin
     
         
    181,819
    8.25
    4/14/2021



    Get the next $ICCC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ICCC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ICCC
    SEC Filings

    See more
    • SEC Form 10-Q filed by ImmuCell Corporation

      10-Q - IMMUCELL CORP /DE/ (0000811641) (Filer)

      5/14/25 4:06:03 PM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • ImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)

      5/14/25 4:05:26 PM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form DEF 14A filed by ImmuCell Corporation

      DEF 14A - IMMUCELL CORP /DE/ (0000811641) (Filer)

      4/24/25 4:08:14 PM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ICCC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

      PORTLAND, Maine, June 05, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that its 2025 Annual Meeting of Stockholders (the "Annual Meeting") will be conducted virtually on Thursday, June 12, 2025, at 9:30 AM ET, as previously disclosed in its Proxy Statement that was filed with the Securities and Exchange Commission ("SEC") on April 24, 2025. The Annual Meeting will be held by remote communication in the form of a telephone conference call and a li

      6/5/25 6:30:00 AM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025

      PORTLAND, Maine, May 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2025. Product Sales Highlights: Product sales during the first quarter of 2025 increased by 11% to approximately $8.1 million compared to the first quarter of 2024.During the six-month period ended March 31, 2025, product sales increased by 28% to approximately $15.8 million compared to the six-month period en

      5/14/25 4:05:00 PM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025

      PORTLAND, Maine, May 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2025 after the market closes on Wednesday, May 14, 2025. The Company is planning to host a conference call the next morning, Thursday, May 15, 2025, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (inter

      5/12/25 8:42:13 AM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ICCC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Fiori Timothy C

      4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)

      4/23/25 12:53:40 PM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 3 filed by new insider Fiori Timothy C

      3 - IMMUCELL CORP /DE/ (0000811641) (Issuer)

      4/7/25 4:15:45 PM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Director Wainman Paul R

      4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)

      9/24/24 8:31:01 AM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ICCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by ImmuCell Corporation

      SC 13D - IMMUCELL CORP /DE/ (0000811641) (Subject)

      8/27/24 4:32:59 PM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13D/A filed by ImmuCell Corporation (Amendment)

      SC 13D/A - IMMUCELL CORP /DE/ (0000811641) (Subject)

      4/16/21 3:21:48 PM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - IMMUCELL CORP /DE/ (0000811641) (Subject)

      2/4/21 11:27:59 AM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ICCC
    Leadership Updates

    Live Leadership Updates

    See more
    • ImmuCell Hires Chief Financial Officer

      PORTLAND, Maine, April 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has hired Timothy C. Fiori to serve as its Chief Financial Officer. Mr. Fiori brings to ImmuCell approximately 24 years of finance and commercial operating experience with IDEXX Laboratories in Westbrook, Maine. He is a 2001 graduate of the University of Maine, Orono with a B.S in Finance. He lives in Raymond, Maine with his wife, Rachel, and enjoys many outdoor activ

      4/7/25 9:00:00 AM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • ImmuCell Appoints Bryan K. Gathagan to Board of Directors

      PORTLAND, Maine, June 21, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that Bryan K. Gathagan has been appointed to its Board of Directors. Mr. Gathagan is the owner and a managing member of broad Thinking, LLC, a management consulting firm and has 25 years of animal health experience. He is a founding member of Animalytix LLC and has served as its Chief Financial and Chief Technology Officer since it began operations in 2010. Prior to Animalytix

      6/21/23 4:05:22 PM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ICCC
    Financials

    Live finance-specific insights

    See more
    • ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

      PORTLAND, Maine, June 05, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that its 2025 Annual Meeting of Stockholders (the "Annual Meeting") will be conducted virtually on Thursday, June 12, 2025, at 9:30 AM ET, as previously disclosed in its Proxy Statement that was filed with the Securities and Exchange Commission ("SEC") on April 24, 2025. The Annual Meeting will be held by remote communication in the form of a telephone conference call and a li

      6/5/25 6:30:00 AM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025

      PORTLAND, Maine, May 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2025. Product Sales Highlights: Product sales during the first quarter of 2025 increased by 11% to approximately $8.1 million compared to the first quarter of 2024.During the six-month period ended March 31, 2025, product sales increased by 28% to approximately $15.8 million compared to the six-month period en

      5/14/25 4:05:00 PM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025

      PORTLAND, Maine, May 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2025 after the market closes on Wednesday, May 14, 2025. The Company is planning to host a conference call the next morning, Thursday, May 15, 2025, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (inter

      5/12/25 8:42:13 AM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care